TG治疗 TGTX 深 沪
等待开盘 04-02 09:30:00 美东时间
33.58
+0.360
+1.08%
华盛通- 最 高34.33
- 今 开33.36
- 成交量 182.62万股
- 最 低 33.325
- 昨 收 33.22
- 总市值 53.62亿
- 52周最高 46.48
- 市盈率 静 12.12
- 换手率 1.14%
- 52周最低 25.28
- 委 比 85.34%
- 总股本 1.60亿
- 历史最高 56.74
- 量 比 0.89
- 振 幅 3.03%
- 历史最低 0.9563
- 每 手 1
- 风险率 3.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
03-31 22:51
TG Therapeutics Enters Into 5-Yr, $750M Senior Secured Credit Facility With Funds Managed By Blue Owl Capital; Co. To Repay Outstanding $250M Senior Secured Credit Facility, Resulting In Net Raise Of $500M In Non-Dilutive Capital
TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital ("Blue Owl"). As
03-19 19:37
TG Therapeutics Announces Presentation Dates For BRIUMVI Data On Relapsing Forms Of Multiple Sclerosis
TGTX announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026
03-06 20:34
财报速睇 | TG治疗 2025财年年度营收6.16亿美元，同比增长87.3%；归母净利润4.47亿美元，同比增长1812.4%
华盛资讯2月28日讯，TG治疗公布2025财年年度业绩，公司年度营收6.16亿美元，同比增长87.3%，归母净利润4.47亿美元，同比增长1812.4%。
02-28 12:17
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.
TG Therapeutics shares are trading lower after the company reported worse-than-...
02-26 22:29
财报速睇 | TG治疗 2025财年Q4营收1.93亿美元，同比增长78.0%；归母净利润0.23亿美元，同比下滑1.3%
华盛资讯2月26日讯，TG治疗公布2025财年Q4业绩，公司Q4营收1.93亿美元，同比增长78.0%，归母净利润0.23亿美元，同比下滑1.3%。
02-26 21:04
财报速睇 | TG治疗 2025财年Q4营收1.93亿美元，同比增长78.0%；归母净利润0.23亿美元，同比下滑1.3%
华盛资讯2月26日讯，TG治疗公布2025财年Q4业绩，公司Q4营收1.93亿美元，同比增长78.0%，归母净利润0.23亿美元，同比下滑1.3%。
02-26 20:47
TG Therapeutics Q4 Earnings Assessment
TG Therapeutics (NASDAQ:TGTX) released its Q4 earnings on Thursday, February 26...
02-26 20:04
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
TG Therapeutics Publishes Five-Year Study On BRIUMVI MS Treatment
At Year 5, 97.7% of continuous-treatment participants and 95.0% of switch participants remained relapse-free.
02-17 20:37
